The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

[1] The purpose of this review paper is to analyze the role of the kidney in glucose homeostasis, emphasizing in SGLT2 inhibition ... Urinary glucose excretion (g/24 h):/DP100 mg: 69.9/DP20 ...

Because SGLT2 inhibitors act on the kidney, and the amount of glucose ... which showed a reduction in urinary glucose excretion of ~85% in T2DM patients with moderate to severe renal impairment ...

Study led by Mount Sinai researcher shows sotagliflozin is the only drug in its class to demonstrate these results ...

So, inhibition of SGLT2 suppresses renal glucose reabsorption and effectively increases urinary glucose excretion and reduces calorific load. The potential of SGLT2 inhibitors to reduce plasma ...

A new study finds SGLT2 inhibitors like Jardiance and GLP-1 drugs like Ozempic provide different benefits depending on the ...

Previous studies have found that SGLT2 inhibitors appear to lower HbA1c less in patients with worse kidney function.” “GLP-1 agonists appear to be less affected by this interaction,” he added.

AstraZeneca is already seeing sales rocket for its SGLT2 inhibitor Farxiga in heart failure, and is expected to gather even more momentum after claiming FDA approval in chronic kidney disease (CKD).

Starting SGLT2 inhibitors led to a lower risk of eGFR decline or incident kidney failure. SGLT2 inhibitors were also linked to reduced amputation and AKI risks. Use of SGLT2 inhibitors was ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

The effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, cardiovascular disease and overall mortality are well known. Now ...